Urinary Tract Infections - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData, the industry analysis specialist's new report, "Urinary Tract Infections (UTI) - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global urinary tract infections market. The report identifies the key trends shaping and driving the global urinary tract infections market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global urinary tract infections sector.
GlobalData's analysis suggests that the global Urinary Tract Infection (UTI) market was worth 1.5m in 2009. The market is expected to be driven by an increase in the usage of newly launched antibiotics for the treatment of complicated UTIs and an increase in the prevalence and diagnosis of UTIs. The patent expiry of one of the most efficacious drug, Levaquin, in 2010 is expected to drive market revenues down. The impact of patent expiry is expected to be softened by the increase in revenue contribution of recently launched carbapenems for the treatment of complicated UTIs.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
The scope of the report includes:
a Annualized global urinary tract infections market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
a Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
a Pipeline analysis data split across different phases by mechanism of action and emerging trends. Key classes of antibiotics in the pipeline include fluoroquinolones, cephalosporins and beta-lactams. It also includes beta-lactamase inhibitors, vaccines and a stable analog of N,N-dichlorotaurine.
a Analysis of the current and future competition in the global UTIs market. Key market players covered include Osel Inc, Cubist Pharmaceuticals, Novexel Inc (AstraZeneca), MerLion Pharmaceuticals GmbH, Tedec-Meiji Farma, S.A. and NovaBay Pharmaceuticals, Inc.
a Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
a Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future of the UTI market.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
a Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
a Develop business strategies by understanding the trends shaping and driving the global urinary tract infections market.